The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
作者信息
Eskazan Ahmet Emre, Elverdi Tugrul, Yalniz Fevzi Firat, Salihoglu Ayse, Ar Muhlis Cem, Ongoren Aydin Seniz, Baslar Zafer, Aydin Yildiz, Tuzuner Nukhet, Ozbek Ugur, Soysal Teoman
机构信息
Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.
出版信息
Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.
PMID:24650055
Abstract
摘要
相似文献
1
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.
2
Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Expert Rev Hematol. 2014 Dec;7(6):697-9. doi: 10.1586/17474086.2014.966679. Epub 2014 Oct 8.
3
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Dec 1;358(9296):1902. doi: 10.1016/S0140-6736(01)06901-X.
4
Targeted cancer therapy: from bench to bedside to patient.
J Clin Oncol. 2014 Feb 1;32(4):268-70. doi: 10.1200/JCO.2013.53.8413. Epub 2013 Dec 23.
5
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Nov 3;358(9292):1478. doi: 10.1016/S0140-6736(01)06571-0.
6
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):117-21. doi: 10.1586/erp.09.1.
7
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Ann Hematol. 2015 Apr;94 Suppl 2(0 2):S249-57. doi: 10.1007/s00277-015-2319-x. Epub 2015 Mar 27.
8
Imatinib for chronic myeloid leukaemia: a NICE mess.
Lancet. 2001 Dec 1;358(9296):1902-3. doi: 10.1016/s0140-6736(01)06902-1.
9
Perspective: combined forces.
Nature. 2013 Jun 27;498(7455):S7. doi: 10.1038/498S7a.
10
Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Am J Med Sci. 2014 Mar;347(3):254-5. doi: 10.1097/MAJ.0000000000000228.
引用本文的文献
1
Comparative Clinical Outcomes and Safety of Generic Versus Original Imatinib in the Treatment of Chronic Myeloid Leukemia: A Real-World Cohort Study from Thailand.
J Clin Med. 2025 May 25;14(11):3695. doi: 10.3390/jcm14113695.
2
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.
Blood Adv. 2021 Sep 14;5(17):3344-3353. doi: 10.1182/bloodadvances.2021004194.
3
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
Cancer Med. 2019 Nov;8(15):6559-6565. doi: 10.1002/cam4.2545. Epub 2019 Sep 10.
4
The tolerability issue of generic imatinib in patients with chronic myeloid leukemia .
Haematologica. 2019 Jul;104(7):e330. doi: 10.3324/haematol.2019.222000.
Zotero 插件